Novo Nordisk (NOVA) Stock Forecast & Price Target

Compare

150 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOVA Analyst Ratings

Hold

1 Buy

6 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOVA Stock 12 Month Forecast

Average Price Target

€37.24

▲(12.69% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €37.24 with a high forecast of €40.90 and a low forecast of €34.81. The average price target represents a 12.69% change from the last price of €33.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"€31","58":"€58","85":"€85","44.5":"€44.5","71.5":"€71.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.89751765,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€40.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.242845859999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€37.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.806398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,44.5,58,71.5,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.05,32.73057828076923,33.41115656153846,34.09173484230769,34.77231312307692,35.45289140384615,36.133469684615385,36.81404796538461,37.49462624615384,38.175204526923075,38.85578280769231,39.53636108846153,40.216939369230765,{"y":40.89751765,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.05,32.44944968153846,32.84889936307692,33.24834904461538,33.647798726153844,34.0472484076923,34.446698089230765,34.84614777076923,35.24559745230769,35.64504713384615,36.04449681538461,36.443946496923076,36.84339617846153,{"y":37.242845859999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.05,32.26203061538461,32.47406123076923,32.68609184615384,32.89812246153846,33.110153076923076,33.32218369230769,33.53421430769231,33.74624492307692,33.958275538461535,34.170306153846155,34.38233676923077,34.59436738461539,{"y":34.806398,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.885,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.103,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.738,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.333,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.567,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€40.90

Average Price Target€37.24

Lowest Price Target€34.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kerry Holford

Berenberg Bank

€49.6→€40.9

Buy

23.74%

Upside

Reiterated

03/11/26

Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)

Evan Seigerman

BMO Capital

€39.16

Hold

18.48%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NYSE: NVO) and Hinge Health, Inc. Class A (NYSE: HNGE)

Michael Nedelcovych

TD Cowen

€39.16→€36.55

Hold

10.58%

Upside

Downgraded

03/09/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NASDAQ: NRSN) and Novo Nordisk (NYSE: NVO)

Thibault Boutherin

Morgan Stanley

€36.55→€34.81

Hold

5.31%

Upside

Upgraded

03/03/26

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

James Quigley

Goldman Sachs

€34.81

Hold

5.31%

Upside

Downgraded

03/03/26

Novo Nordisk downgraded to Neutral from Buy at Goldman SachsNovo Nordisk downgraded to Neutral from Buy at Goldman Sachs

Martin Brenoe

Nordea Markets

―

Hold

―

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea

Emmanuel Papadakis

Deutsche Bank

―

Hold

―

Downgraded

02/23/26

Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank

Rajesh Kumar

HSBC

€40.9→€46.99

Hold

42.17%

Upside

Reiterated

12/10/25

Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC

Jasper Hellweg

Argus Research

―

Hold

―

Downgraded

12/05/25

Novo Nordisk downgraded to Hold from Buy at ArgusNovo Nordisk downgraded to Hold from Buy at Argus

Richard Vosser

J.P. Morgan

―

Buy

―

Reiterated

11/24/25

Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan

Sachin Jain

Bank of America Securities

€50.19

Hold

51.85%

Upside

Reiterated

10/09/25

Simon Baker CFA

Rothschild & Co Redburn

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Peter Verdult

Exane BNP Paribas

€46.99

Hold

42.17%

Upside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kerry Holford

Berenberg Bank

€49.6→€40.9

Buy

23.74%

Upside

Reiterated

03/11/26

Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)

Evan Seigerman

BMO Capital

€39.16

Hold

18.48%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NYSE: NVO) and Hinge Health, Inc. Class A (NYSE: HNGE)

Michael Nedelcovych

TD Cowen

€39.16→€36.55

Hold

10.58%

Upside

Downgraded

03/09/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NASDAQ: NRSN) and Novo Nordisk (NYSE: NVO)

Thibault Boutherin

Morgan Stanley

€36.55→€34.81

Hold

5.31%

Upside

Upgraded

03/03/26

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

James Quigley

Goldman Sachs

€34.81

Hold

5.31%

Upside

Downgraded

03/03/26

Novo Nordisk downgraded to Neutral from Buy at Goldman SachsNovo Nordisk downgraded to Neutral from Buy at Goldman Sachs

Martin Brenoe

Nordea Markets

―

Hold

―

Downgraded

02/24/26

Novo Nordisk downgraded to Hold from Buy at NordeaNovo Nordisk downgraded to Hold from Buy at Nordea

Emmanuel Papadakis

Deutsche Bank

―

Hold

―

Downgraded

02/23/26

Novo Nordisk downgraded to Hold from Buy at Deutsche BankNovo Nordisk downgraded to Hold from Buy at Deutsche Bank

Rajesh Kumar

HSBC

€40.9→€46.99

Hold

42.17%

Upside

Reiterated

12/10/25

Novo Nordisk price target raised to $54 from $47 at HSBCNovo Nordisk price target raised to $54 from $47 at HSBC

Jasper Hellweg

Argus Research

―

Hold

―

Downgraded

12/05/25

Novo Nordisk downgraded to Hold from Buy at ArgusNovo Nordisk downgraded to Hold from Buy at Argus

Richard Vosser

J.P. Morgan

―

Buy

―

Reiterated

11/24/25

Novo selloff on Alzheimer's miss overdone, says JPMorganNovo selloff on Alzheimer's miss overdone, says JPMorgan

Sachin Jain

Bank of America Securities

€50.19

Hold

51.85%

Upside

Reiterated

10/09/25

Simon Baker CFA

Rothschild & Co Redburn

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Peter Verdult

Exane BNP Paribas

€46.99

Hold

42.17%

Upside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+0.86%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.86% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

4/7 ratings generated profit

Average Return

+3.73%

Copying Richard Vosser's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +3.73% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+21.13%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +21.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVA Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOVA has received 6 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. NOVA average Analyst price target in the past 3 months is 37.24.

Each month's total comprises the sum of three months' worth of ratings.

NOVA Financial Forecast

NOVA Earnings Forecast

Next quarter’s earnings estimate for NOVA is €0.80 with a range of €0.66 to €1.35. The previous quarter’s EPS was €0.83. NOVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year NOVA has Performed in-line its overall industry.

NOVA Sales Forecast

Next quarter’s sales forecast for NOVA is €10.04B with a range of €9.19B to €12.93B. The previous quarter’s sales results were €10.70B. NOVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year NOVA has Performed in-line its overall industry.

NOVA Stock Forecast FAQ

What is DE:NOVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 37.24.

What is DE:NOVA’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 12.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold, which is based on 1 buy ratings, 6 hold ratings and 0 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 37.24. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €40.90 ,and the lowest forecast is €34.81. The average share price target represents 12.69% Increase from the current price of €33.05.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of DE:NOVA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (NOVA) Stock Forecast & Price Target

NOVA Analyst Ratings

NOVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NOVA Analyst Recommendation Trends

NOVA Financial Forecast

NOVA Earnings Forecast

NOVA Sales Forecast

NOVA Stock Forecast FAQ

Detailed List of Analyst Forecasts